|  |  |  |  | Number of carriers of HLA alleles associated with DILI in our cohort (n= 385) | |
---|---|---|---|---|---|---|
Drug | HLA allele | Reaction (ethnicity) | Odds ratio (95% CI) | Reference | Hmz | Htz |
Drug-induced hypersensitivity reactions | Â | Â | Â | Â | Â | Â |
   Abacavir | B*57:01 | Hypersensitivity (all) | 117 (29-481) | [14] | 1 | 25 |
   Carbamazepine | B*15:02 | SJS/TEN (Han Chinese) | 2,504 (126-49,522) | [4] | 1 | 6 |
 | A*31:01 | All phenotypes (Caucasian) | 12.12 (4.03-20.65) | [17] | 0 | 23 |
   Allopurinol | B*58:01 | SJS (Han Chinese) | 580.3 (34.4-9,780.9) |  | 0 | 6 |
 |  | SJS (Caucasian) | 80 (34-187) |  |  | |
   Nevirapine | DRB1*01:01 | Hypersensitivity (Caucasian) | 4.8 (1.3-16.8) | [16] | 3 | 52 |
   Lamotrigine | B*38 | SJS/TEN (Caucasian) | 6.8 (2.6-18) | [12] | 0 | 7 |
Drug-induced liver injury | Â | Â | Â | Â | Â | Â |
   Flucloxacillin | B*57:01 | DILI (Caucasian) | 80.6 (22.8-284.9) | [6] | 1 | 25 |
   Ximelagatran | DRB1*07:01 | DILI (Caucasian) | 4.4 (2.2-8.9) | [11] | 10 | 91 |
 | DQA1*02:01 |  | 4.4 (2.2-8.1) |  | ND | ND |
   Lumiracoxib | DRB1*15:01 | DILI (Caucasian) | 7.5 (5.0 to 11.3) | [21] | 10 | 100 |
 | DQA1*01:02 |  | 6.3 (4.1 to 9.6) |  | ND | ND |
 | DQB1*06:02 |  | 6.9 (4.6 to 10.3) |  | 8 | 90 |
   Co-amoxiclav | DRB1*15:01 and | DILI (Caucasian) | 2.8 (2.1 to 3.8) | 10 | 100 | |
 | DQB1*06:02 |  |  |  | 8 | 90 |
 | A*02:01 |  | 2.3 (1.8 to 2.9) |  | 46 | 153 |
   Antituberculosis (isoniazid, rifampicin, pyrazinamide) | DQB1*02:01 | DILI (Indian) | 1.9 (1.0 to 3.9) | [20] | 20 | 143 |
   Lapatinib | DQA1*02:01 | DILI (Caucasian) | 2.2 (1.1 to 5.7) | [22] | ND | ND |
 |  |  | 9.0 (3.2 to 27.4) |  |  |  |
 | DRB1*07:01 |  | 6.9 (2.5 to 19.9) |  | 10 | 91 |
 | DQB1*02:02 |  | 6.9 (2.5 to 19.6) |  | 0 | 0 |
   Diclofenac | DRB1*13 | DILI (Caucasian) | - | [5] | - | - |
   Clometacin | B*08 | DILI | - | [19] | - | - |
   Ticlopidine | A*33:03 | DILI (Japanese) | 13.0 (4.4 to 38.6) | [9] | 1 | 8 |